Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk

Eur J Prev Cardiol. 2020 Mar;27(5):556-558. doi: 10.1177/2047487319839179. Epub 2019 Mar 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Activities of Daily Living
  • Aged
  • Anticholesteremic Agents / therapeutic use*
  • Biomarkers / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol, LDL / blood*
  • Drug Therapy, Combination
  • Female
  • Health Status
  • Heart Disease Risk Factors
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / diagnosis
  • Hypercholesterolemia / drug therapy*
  • Male
  • Mental Health
  • Middle Aged
  • PCSK9 Inhibitors*
  • Prospective Studies
  • Quality of Life*
  • Risk Assessment
  • Serine Proteinase Inhibitors / adverse effects
  • Serine Proteinase Inhibitors / therapeutic use*
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL
  • PCSK9 Inhibitors
  • Serine Proteinase Inhibitors
  • PCSK9 protein, human